Serengulam V Govindan

6558669, May 6, 2003

Aug 28, 1997

08/919477

Serengulam V. Govindan - Summit NJ
Gary L. Griffiths - Morristown NJ

Immunomedics, Inc. - Morris Plains NJ

C07K 506

4241781, 4241791, 530324, 530345, 5303911, 5303913, 514 12, 436512, 436536

Methods are described for conjugating radioiodinated peptides or carbohydrate structures to proteins with improved yields and qualities of conjugates. In one method, specially designed radioiodinated bifunctional peptides containing nonmetabolizable amide bonds are coupled to antibodies. In a second method, radioiodinated nonmetabolizable bifunctional peptides, which also contain aminopolycarboxylates, are coupled to antibodies. In a third method, radioiodinated bifunctional aminopolycarboxylates are coupled to antibodies. In a fourth method, a hydrazide-appended antibody is coupled to a radioiodinated carbohydrate or a thiolated antibody is coupled to a hydrazide-appended and radioiodinated carbohydrate. In a fifth method a monoderivatized cyanuric chloride is used to conjugate thiolated antibody. Radioiodinated residualizing antibody conjugates made by these methods are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.

6663866, Dec 16, 2003

Jun 29, 2000

09/605873

Serengulam V. Govindan - Summit NJ

Immunomedics, Inc. - Morris Plains NJ

C07K 506

4241781, 4241791, 435 71, 530322, 530385

Methods are described for conjugating radioiodinated peptides to non-metabolizable carbohydrates with improved yields and qualities of conjugates. Radioiodinated residualizing antibody conjugates comprising a carbohydrate-appended peptide are also provided. The instant radioiodinated residualizing antibody conjugates are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.

6818742, Nov 16, 2004

Oct 26, 2000

09/696740

Serengulam V. Govindan - Summit NJ
Gary L. Griffiths - Morristown NJ

Immunomedics, Inc. - Morris Plains NJ

A61K 3800

530345, 530324

Methods are described for conjugating radioiodinated non-metabolizable peptides to proteins and antibodies with improved yields and qualities of conjugates. Radioiodinated residualizing antibody conjugates comprising any aminopolycarboxylate-appended peptide, or any carbohydrate-appended peptide, are also provided. Additionally, methods are described for conjugating radioiodinated aminopolycarboxylates to proteins and antibodies, as well as for conjugating radioiodinated non-metabolizable carbohydrates to proteins and antibodies by a variety of chemical approaches. The instant radioiodinated residualizing antibody conjugates are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.

6858705, Feb 22, 2005

Oct 16, 2003

10/686436

Serengulam V. Govindan - Summit NJ, US
Gary L. Griffiths - Morristown NJ, US

Immunomedics, Inc. - Morris Plains NJ

A61K038/00

530345

Methods are described for conjugating radioiodinated non-metabolizable peptides to proteins and antibodies with improved yields and qualities of conjugates. Radioiodinated residualizing antibody conjugates comprising any aminopolycarboxylate-appended peptide, or any carbohydrate-appended peptide, are also provided. Additionally, methods are described for conjugating radioiodinated aminopolycarboxylates to proteins and antibodies, as well as for conjugating radioiodinated non-metabolizable carbohydrates to proteins and antibodies by a variety of chemical approaches. The instant radioiodinated residualizing antibody conjugates are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.

7147856, Dec 12, 2006

Apr 11, 2003

10/411370

Serengulam V. Govindan - Summit NJ, US

Immunomedics, Inc. - Morris Plains NJ

A61K 39/00
A61K 39/385

4241781, 4241791, 514 12, 530324, 530345, 930 21

Methods are described for conjugating radioiodinated peptides or carbohydrate structures to proteins with improved yields and qualities of conjugates. In one method, specially designed radioiodinated bifunctional peptides containing nonmetabolizable amide bonds are coupled to antibodies. In a second method, radioiodinated nonmetabolizable bifunctional peptides, which also contain aminopolycarboxylates, are coupled to antibodies. In a third method, radioiodinated bifunctional aminopolycarboxylates are coupled to antibodies. In a fourth method, a hydrazide-appended antibody is coupled to a radioiodinated carbohydrate or a thiolated antibody is coupled to a hydrazide-appended and radioiodinated carbohydrate. In a fifth method a monoderivatized cyanuric chloride is used to conjugate thiolated antibody. Radioiodinated residualizing antibody conjugates made by these methods are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.

7230085, Jun 12, 2007

Nov 27, 2002

10/305268

Gary L. Griffiths - Morristown NJ, US
Hans J. Hansen - Picayune MS, US
Serengulam V. Govindan - Summit NJ, US
Michelle Losman - South Orange NJ, US
Zhengxing Qu - Warren NJ, US

Immunomedics, Inc. - Morris Plains NJ

C12P 21/08
C07K 16/44
G01N 33/534
A61K 51/10

5303873, 5303881, 5303889, 5303913, 530304, 436548

The present invention relates to an antibody or antibody fragment that binds to 1,4,7,10-tetrazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA),which is bound to an alkyl-amino group through one of its pendant carb. oxyl groups.

7238785, Jul 3, 2007

Mar 3, 2003

10/377121

Serengulam Govindan - Summit NJ, US
Zhengxing Qu - Warren NJ, US
Hans Hansen - Picayune MS, US
David Goldenberg - Mendham NJ, US

Immunomedics, Inc. - Morris Plains NJ

C12P 21/08
C07K 16/00
A61K 39/395
C12P 21/04
G01N 33/574

5303873, 53038822, 5303888, 53038885, 5303913, 5303917, 4241331, 4241361, 4241431, 4241551, 4241561, 4241811, 435 696

This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.

7259249, Aug 21, 2007

Dec 1, 2004

11/000500

Gary L. Griffiths - Morristown NJ, US
Serengulam V. Govindan - Summit NJ, US

Immunomedics, Inc. - Morris Plains NJ

C07K 1/00

530400, 514 6

Improved synthesis methods are provided for preparing conjugates of proteins and chelating agents. In the synthesis methods, non-stable bonds are hydrolyzed after the conjugate is synthesized, for example by treating the conjugate with a quenching agent. The synthesis method provides conjugates that are substantially free of non-stable bonds between the protein and the chelating agent, such that the chelating agent is less likely to dissociate with the conjugate after the conjugate has been stored for extended periods. The conjugate may be useful for therapeutic or diagnostic methods.